Home Blog Page 8319

Vaccine ethics

Even with the hopeful news of successive vaccines being approved for use in various countries, a major issue confronting many societies is who should get vaccinated first. The problem exists since it will be months — and in poorer countries, perhaps years — before the supply of vaccines is actually enough to meet demand.

Even rich countries struggle with the issue. While there is a consensus that healthcare personnel ought to be among the first priorities, a good deal of debate and difference follows over who should be next. A good model of careful thinking however is set by the permanent commission on vaccination of Germany’s Robert Koch Institute.* It first lays down the social objectives, namely: to minimize death and hospitalizations; to protect people who are professionally exposed to the disease; to minimize further transmission; and to sustain public life and the continuity of government functions. (Note that if the desired objectives had been different, e.g., minimizing economic disruption, the corresponding vaccination priorities would also have differed.)

In the event, with social objectives set, vaccination priorities consistent with them can be determined. These are roughly as follows: first in line are the elderly, with diminishing priority as age declines to 60; second in line are personnel in medical institutions with priority based on the risk of exposure (e.g., frontline doctors and nurses in hospitals ahead of those in private clinical practice or administration); third, persons with underlying conditions carrying a risk of serious illness, e.g., cancer, diabetes, cardiovascular disease; fourth, teachers, school personnel, and persons doing precarious work; fifth — note only the fifth — are key government personnel at national and local levels; and finally all other persons less than 60 years old.

The science and ethics behind these priorities are clear. If the aim is to minimize deaths and hospitalization, immunizing the elderly is the most direct route, since the effects of infection are known to be most severe among the elderly. (In the Philippines, three-fourths of all infections are among the below-50 age group, but roughly 60% of hospitalizations and 80% of deaths occur in the 50 to 89-year-old age bracket.) The same logic holds for prioritizing frontline health care personnel, who must immediately be protected against the disease if they are to continue working and not infect the people they attend to. On the other hand the lower priority given to teachers is also understandable, since their risk of exposure is lower and contingent on the mode of instruction to begin with. Of course, a diabetic 60-year-old teacher might still get higher priority, not because she is a teacher but because of her age and underlying medical condition.  The fifth priority accorded to high government officials — quite apart from delicadeza — stems from their greater ability to avoid risk and their easier access to quality healthcare if they do get infected. Germany’s chancellor Angela Merkel set an example in this regard during her New Year’s address when she said: “I too will be vaccinated — when it is my turn.”

Here at home, one must wonder whether the same thoughtful science guided by ethics and local conditions has gone into the government’s own vaccine program. News reports thus far fail to give the impression of a well-thought-out plan. The public is presented instead with a hodge-podge enumeration of supposed priority groups with no detail regarding their relative importance or the sequence of the rollout. Beyond the clear case of medical frontliners, the list seems more attuned to a prioritization not of the civilian population but of government agencies and employees. Hence it first enumerates “personnel” from departments of education, social welfare, jail management, and customs (!) without distinction as to function. But seniors and the poor “will also” be among the first, and — “based on President Duterte’s wishes” — the police and the military as well. Where almost everyone is a priority, one wonders if anyone really is.

One wonders exactly how such priorities will be implemented in practice. Would an able-bodied soldier or policeman get the vaccine ahead of a 65-year-old with diabetes? Would a customs inspector be inoculated before a factory or transport worker? Or a school principal before an elderly urban poor person? More important than one or the other answer is: why or why not?

This need for a painstaking delineation of vaccine-priorities is based on an economic reality: for an extended period, the supply of vaccines will be inelastic and must be quantitatively rationed to those who are most in need. The invisible hand of the market fails to work its wonders in these cases, since even an above-normal price would do nothing to increase supply, nor is a suppression of demand acceptable on humanitarian grounds. For the same reason (i.e., one that should be taught more in Econ 11), price-controls in areas cut off by natural disasters are a justifiable departure from the otherwise reliable course of letting market forces decide the allocation of scarce resources. In such crises, the limited supply of life-preserving means must be allocated based on humanitarian need and explicit social-welfare criteria, rather than through accustomed privilege and buying power. Flouting social priorities during such times of national crisis, e.g., through hoarding or price-gouging, amounts to a crime.

Now zero in on recent events. A slowly-mushrooming scandal is the revelation that members of the President Duterte’s innermost circle — including some cabinet members, his own close-in Presidential Security Group (PSG), and some allege even Duterte himself — had surreptitiously secured the Chinese Sinopharm/CNBG vaccine and had themselves secretly inoculated. Various administration officials have since twisted and turned to play down the incident, seeking to limit the damage by painting it as a purely private matter, where: (a.) the drug was just “donated” (later revised to “smuggled” so its origin is presumably no longer traceable); (b.) the vaccine was “self-administered” by the soldiers themselves (so no physician or other accomplice can be called to account); (c.) the vaccination was “purely voluntary” on the part of the soldiers (to pre-empt the obvious human-rights violation of coercing subordinates to be vaccinated with an unapproved drug); and, (d.) that neither the president nor any of the PSG’s higher-ups knew anything about the matter until after the fact (which strains credulity given the president’s vaunted omniscience and ₱4.5-billion intelligence fund). This leaves the PSG head to take sole responsibility and fall on his sword. (But not to worry, there’s always a safety net and reward for the steadfast. Main thing is to stop the contagion of scandal right there.)

Much of the criticism of these actions has thus far centered on how the vaccine was still FDA-unapproved and therefore possibly unsafe or ineffective. Such criticisms miss the point however. It is precisely because the Chinese vaccine is possibly or likely to be effective that its hoarding, misappropriation, and private use — particularly by key officials — is objectionable. At a minimum, the proper action should have been to entrust the vaccine supply — approved or unapproved, donated, smuggled or otherwise — to the health department for possible future distribution. (As an aside, the Chinese government has since approved the Sinopharm vaccine for general public use; and there is little doubt it will ultimately be approved by the FDA here as well.)

The incident is a scandal because it is a big slap in the face of a government that pretends to any attempt at a fair social prioritization and orderly distribution of scarce, life-saving vaccines. It is specious to reduce the matter to a private action that harms only the participants themselves: in the midst of dire scarcity, each private action has palpable social repercussions; every act of misappropriation is a deprivation of someone more deserving. The most cogent observation that goes to the heart of the matter came from a nurse who said: “Parang inapi naman nila ‘yung health workers. Talagang ipinakita nila na hindi priority. (It is like they abused the health workers. They really showed that they are not a priority.)” To extend the metaphor of a calamity, these actions are tantamount to government workers hoarding and gorging on donated relief goods instead of distributing them to those most in need.

Unless the full truth is revealed and those truly responsible are held to account, this sordid event bodes ill for popular trust in the seriousness of the government’s vaccine distribution plan. It is cold comfort that the plan itself to date is still murky in its principles, priorities, and operational implementation. Even before these details can be sorted out, however, the plan’s credibility has already been tainted. The red flag has been raised that not only may safety protocols be breached, but that the orderly and fair vaccine distribution may be corrupted by queue-jumping, supply-diversion, patronage, deceit, and bribery, with priority given to the highest bidder — or the most connected to the center of power.

Rather than take this credibility issue dead-seriously, however, administration officials have pooh-poohed the matter and addressed it instead by: first covering up the incident and denying it even happened. Second, when that failed, disavowing any knowledge of it and shifting the responsibility entirely upon the lowly soldiers themselves. And finally, deflecting attention away from the embarrassing issue by throwing a smoke bomb regarding corrupt public engineers and congressmen (all noise, with little evidence anyway) meant to crowd out news of the matter.

Oh, well, at least now we know what “Mask, Hugas, Iwas” (Mask, Wash, Avoid) really means.

*“STIKO-Empfehlung zur COVID-19 Impfung.” Advance copy of Epidemiologisches Bulletin dated Jan. 14, 2021.

 

Emmanuel S. De Dios is professor emeritus at the University of the Philippines School of Economics.

Pinoy vaccination

An otherwise comedic story if not for its disastrous effect could have well happened in the Philippines.

A clinic in West Virginia blundered and injected 42 people not with a COVID-19 vaccine but with an experimental antibody cocktail. (Also, the procedure for the use of the antibody treatment was wrong. It is administered through infusion, not inoculation.)  This tragedy was attributed to a “breakdown in the process” and to “human errors.”

And across the United States, the vaccine distribution is plagued by the lack of resources and logistical complications. A typical story is that the vaccines are available but are stored in hospitals and not given to the most vulnerable people. Worse are accounts of health workers who have refused vaccination.

As a consequence of all this, the US government sorely missed the goal of having 20 million people vaccinated by end-2020. By year end, the Centers for Disease Control and Prevention reported that 2.8 million people received the first dose of the vaccine. Even assuming that this was a conservative report, we would still conclude that the performance was way below the target.

It goes without saying that such problems pertaining to disorganization, inefficiency, and incompetence are more pronounced in the Philippines.

So, is it a blessing in disguise that Philippine vaccination is not right out of the gate? Not really.  The point though is that we must learn the lessons from the front-runners. But more importantly, we need to internalize lessons from our own experiences in fighting COVID-19, especially our failings.

Many lessons have to be learned in rolling out our vaccination program. I emphasize a few, namely:

First, do not treat the first-generation vaccines as silver bullets. The efficacy of the first vaccines has been established in clinical trials, but the real world is different. By all means, have the approved vaccines, but be prepared for twists and turns. The ultimate success of the vaccine depends on factors that we cannot predict like the actual and long-term effectiveness of the vaccines.

A fine difference exists between efficacy and effectiveness. Here’s a relevant passage from Carl Zimmer, “2 Companies Say Their Vaccines are 95% Effective. What Does That Mean?” This was published in The New York Times on Nov. 20, 2020 and updated on Dec. 4, 2020:

“Efficacy is just a measurement made during a clinical trial. ‘Effectiveness is how well the vaccine works out in the real world,’ said Naor Bar-Zeev, an epidemiologist at the Johns Hopkins Bloomberg School of Public Health.

“It’s possible that the effectiveness of coronavirus vaccines will match their impressive efficacy in clinical trials. But if previous vaccines are any guide, effectiveness may prove somewhat lower.”

The second lesson, which follows from avoiding the temptation to devote all efforts and resources to the vaccination program, is to do well in previous tasks. The truth is, much still has to be done to improve the Philippine capacity for case finding, testing, screening, quarantining the infected and those with symptoms, and contact tracing. The vaccination program must go hand in hand with the above interventions.

The third lesson is to have effective strategic communication. Strategic communication — one that is clear, accurate, transparent, and persuasive — is in fact the strategy.

Again, the Philippines is wanting in this area. Different authorities contradict one another. Worse, some officials are the carriers of fake news. Remember the statement of President Rodrigo Duterte that gasoline can be used as a disinfectant against COVID-19? He was probably joking, but it was a bad joke. Some folks take his every utterance seriously.

Moreover, effective communication must convince the population to get the COVID-19 vaccine. We have to contend with the sad reality that a significant number of our people fear vaccination, borne out of experience. Thousands of families, especially their schoolchildren, suffered from what is known as the Dengvaxia controversy.

Despite the advance warning from some quarters from the scientific and health community, the Department of Health in the previous administration swiftly introduced Sanofi Pasteur’s questionable Dengvaxia vaccine against dengue. Eventually, but with the damage already done, Sanofi warned that the vaccine posed a higher risk of a severe case of dengue for previously uninfected persons.

Fourth, recognizing that the virus cannot be annihilated soon despite the introduction of the vaccine, we have to continue adhering to the protocols of self-protection, especially physical distancing. But social compliance depends to a significant extent on how leaders themselves follow the rules.

A survey and study done by the University College London showed a decrease in social compliance (and Brits typically abide by rules!) when the public found out that their leaders avoided or violated the rules. Making excuses and using loopholes make things worse in gaining trust.

The administration thus should no longer tolerate and should condemn actions such as the Chief of the Philippine National Police having a mañanita (early morning party) and the President’s Spokesperson enjoying the company of dolphins during a strict lockdown or singing loudly in a bar during community quarantine. Pinoys also follow their leaders’ example.

Last but not least, we must recognize that the vaccination program must be a whole-of-society approach. The government, the private sector, and the civil society organizations must coordinate efforts and unite in common strategies for the transparent acquisition and equitable distribution of the vaccine.

Up to now, apart from receiving general pronouncements, the public is not fully informed about the framework, goals, and strategies for vaccine allocation and distribution. We need a bipartisan effort and a broad coalition that will rally around transparency, accountability, equity, and efficiency in the formulation and implementation of the vaccination program. 

 

Filomeno S. Sta. Ana III coordinates the Action for Economic Reforms.

www.aer.ph

2020: Fintech’s most challenging year

2020 was the most difficult year in our lifetime yet. Amidst the maelstrom of this health crisis, a new global order emerged.

The fintech industry found itself at the forefront as people navigate this new way of life. Industry players worked double time to thrive and survive. The primary goal is to ease the Filipinos’ quick migration to and adoption of digital.

Digital payments technology has been in existence for 15 years. In fact, the Philippines pioneered it globally. But it was only during this health crisis that it reached a critical mass. The proliferation of mobile phones triggered this evolution in social behavior. This came with the emergence of e-commerce growing at a rate of 32%. About three years ago, online business mushroomed. Now, it is experiencing exponential growth. We have seen an era of apps surplus globally with over four million. And there are more to come, catering to all sorts of conceivable human interface.

The government’s digital disbursements of social amelioration was one of the highlights this year. Scaling electronic transactions across segments will result in achieving a digital economy. Limited mobility and less physical interaction are primary to pushing digital. Even post-COVID, digital would see more traction.

The Bangko Sentral ng Pilipinas (BSP) released a record number of enabling regulations. This has been an unprecedented move to realize its twin goals: one is shifting 50% of financial transactions to digital, and the other is moving 70% of adult Filipinos into the formal financial system.

Among these milestone regulations are the digital bank and open finance frameworks. BSP Governor Benjamin Diokno underscores digital banks’ relevance in the financial ecosystem.

The FinTech Alliance has remained a thought leader in the industry. It has submitted several position papers to regulators BSP, the Securities and Exchange Commission, the National Privacy Commission, and Congress. It covered subjects on various pieces of legislations and draft regulations. These include digital tax, Bayanihan Acts I and II, and interest capping, among others. It also covered topics on green finance and loan payment moratorium. And issues on personal data processing for loan-related transactions. This includes supporting the government’s push for the full implementation of the national ID.

With the growing digital adoption, it is crucial to ensure its security and the users. Massive cybersecurity awareness amongst consumers has been a primary thrust. Unlocking the potential of green finance technologies will be a 2021 priority. Well aligned with the Paris Agreement and the Sustainable Development Goals (SDG). It will also play a big role in the collection of climate-related data. As there is a need to quantify the cost of climate-related risks. Climate change will be top of our agenda. We have seen a series of typhoons with severe flooding in the country. And this has reached an alarming state. Reducing the carbon footprint must be a universal commitment amongst industry players.

The Alliance was among the signatories of the manifesto for shared prosperity. This initiative was done with 25 Philippine Business Groups. It is a collective long-term aspiration amongst Filipinos on what they want for themselves, and for the country in the next 25 years. It is the result of a long-term visioning process that began in 2015. This was in collaboration with the National Economic Development Authority, and an advisory committee composed of government, private sector, academe and civil society.

 

Lito Villanueva is the founding chairman of the FinTech Alliance.ph. He is the Executive Vice-President and Chief Innovation and Inclusion Officer of RCBC and concurrently the Chief Digital Transformation Advisor for the Yuchengco Group of Companies. He is also a prime mover in the Philippine fintech industry, with over 60 global and regional accolades for digital innovations.

Understanding the new COVID-19 strain

Paranoia is sweeping the land again as a new strain of the coronavirus has emerged.

Last month, a single passenger from the United Kingdom tested positive for the mutated strain. Since then, the Philippine government has declared a travel ban on all flights coming in from the UK until mid-January. In addition, a travel ban and a mandatory 14-day quarantine has been imposed for all those arriving from countries that reported to have the new strain, including Singapore, Australia, Japan, and 17 other countries. The quarantine shall be imposed regardless of the results of a polymerase chain reaction (PCR) test.

In Mindanao, inter-island travel to and from Sabah and Sulu has been prohibited and a naval blockade installed as the mutated virus was recently detected in Sabah.

The new virus strain is said to be 70% more transmissible than the original Wuhan strain. It is also said to result in more serious symptoms, especially among the immunocompromised. The infectiousness of the virus, coupled with its lethality, has made this new strain a more fatal one. It has made this pandemic harder to manage.

But before panic overcomes reason, we must understand the dynamics of this new strain.

The genetic code of the coronavirus is written in its RNA. RNA naturally mutates when it replicates. Some mutations make the virus weaker leading it to die, while others become stronger. In fact, the strain that arrived in Europe earlier this year was already a mutated version of the original Wuhan strain. The coronavirus is similar to the influenza virus in that it is constantly changing. Hence, the need to have new flu shots every year.

Two characteristics make the new strain from the UK more lethal. First, its spike protein allows it to be more effective in binding, entering, and reproducing in human cells. This is why it is more infectious than the original Wuhan strain. (Although it’s been said that this new strain is 70% more transmittable, this is only an inferred estimate, not a proven fact.) Second, its spike protein allows it to be more resistant to antibodies. In other words, it is more robust, more persistent and results in more serious symptoms. Note, a similar strain of the virus was also detected in South Africa where it mutated independently from that of the UK. This tells us that the virus can mutate anywhere on its own, without transmission from a foreigner.

So the next question is — if a virus can mutate the functionality of its spike protein over time, can it mutate to a point where it becomes strong enough to resist the vaccine (also called immunological escape or vaccine escape)? Yes it can. But this does not happen overnight. It takes a series of mutations for a virus to develop enough changes in its spike protein to achieve vaccine escape.

The new mRNA vaccines, particularly those from Pfizer and Moderna, produce a purified spike protein that causes immune responses like fever, muscle aches, and headaches. All these are indicative of our immune system revving-up in response to the vaccine. These antibodies have a neutralizing effect that can knock-out the virus through mass attack. The virus must mutate quite a bit to evade it. Studies suggest that it will take five years for the virus to achieve this mutation. Hence, from what we know today, there is no immediate danger of vaccine escape. The vaccines are strong enough to overcome even the more robust mutated strain of the COVID-19 virus, for now.

So, how do you prevent the virus from mutating into one that can resist the vaccine? By preventing the virus from replicating. In this regard, governments around the world must vaccinate as many people as they can, as quickly as they can. It is also important to remain fastidious about safety protocols like social distancing, hand washing, and mask wearing to suppress viral replication.

The fact that the vaccines are strong enough to resist even the new strain of the virus should not lead us to complacency. We still need to be vigilant since there is no telling how the virus will mutate in the future.

We hope that this time around, the IATF-EID has learned its lesson and will not make the same mistakes as it did before. First of all, it should raise travel bans as quickly as possible and not pussyfoot around China (curiously, mainland China is not included in the list of countries affected by our travel ban, as of this writing). It must establish nationwide testing and genotyping facilities to monitor the spread of the virus and how it is mutating.

Above all, it must not impose a militaristic lockdown, like the ECQ, which the world now recognizes and calls “the dumb bomb.” It is referred to as such for how it uselessly causes severe economic consequences without curtailing the virus’ spread. Rather, it must utilize the “smart bomb,” like South Korea and Vietnam did, which involves aggressive testing, tracking, treatment of the infected and the isolation carriers.

It is also important that the government not be a fear monger since fear is what killed our consumer driven economy in the first place.

As for the rest of the citizenry, let us be informed and vigilant, not afraid.

 

Andrew J. Masigan is an economist

andrew_rs6@yahoo.com

Twitter @aj_masigan

India approves AstraZeneca, local COVID vaccines

NEW DELHI — India’s drugs regulator on Sunday gave final approval for the emergency-use of two coronavirus vaccines, one developed by AstraZeneca and Oxford University and the other by local company Bharat Biotech and a state-run institute.

The decisions mark the first vaccine approvals for the world’s second-most populous country, which after the United States, has recorded the most infections of the coronavirus disease.

It is now expected to start a massive immunization programme within about a week, a government official said, and hopes to inoculate 300 million of its 1.35 billion people free of charge in the first six to eight months of this year.

The AstraZeneca/Oxford shot, already approved in Britain, Argentina and El Salvador, will take the lead and Bharat Biotech’s COVAXIN will be administered under stricter conditions given no efficacy data has been released for it.

“It’s now time to reap the benefits of the robust supply chain infrastructure we’ve put in place for quick and equitable distribution of the vaccine,” said Harsh Vardhan, the health minister of India, which is the world’s biggest vaccine producer and exporter.

“Urge all citizens to entrust the stringent protocols followed for ensuring safety, efficacy and immunogenicity of the approved vaccines.”

Drugs Controller General of India V.G. Somani said the overall efficacy of the AstraZeneca/Oxford vaccine was 70.42%, while Bharat Biotech’s COVAXIN was “safe and provides a robust immune response”.

The British-developed AstraZeneca/Oxford shot is being made locally by the Serum Institute of India (SII) and will be branded COVISHIELD, while Bharat Biotech has teamed up with the government-run Indian Council of Medical Research.

A lawmaker from Prime Minister Narendra Modi’s nationalist party had earlier complained about the apparent preference for the foreign-made vaccine instead of the local one, whose approval has also raised questions about a lack of transparency in the process.

“Vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situations,” Mr. Somani, the head of the Central Drugs Standards Control Organization, said at a news conference, reading from a written statement. Mr. Somani did not take questions.

Both vaccines will be administered in two doses and stored at 2-8° degrees Celsius (36 to 48°F), he said, without clarifying what intervals between shots were being recommended. Sources said on Saturday the doses would have to be given four weeks apart.

Mr. Somani said the Bharat Biotech vaccine had been approved “in public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains.”

Prime Minister Narendra Modi welcomed the approvals.

“It would make every Indian proud that the two vaccines that have been given emergency use approval are made in India!” he said on Twitter, calling it a sign of a “self-reliant” country.

SII, the world’s biggest vaccine producer, has already stockpiled more than 50 million doses of the AstraZeneca/Oxford vaccine even before securing a formal supply deal with the government.

“All the risks @SerumInstIndia took with stockpiling the vaccine, have finally paid off,” CEO Adar Poonawalla said on Twitter. “COVISHIELD, India’s first COVID-19 vaccine, is approved, safe, effective and ready to roll-out in the coming weeks.”

CONTROVERSY
The AstraZeneca/Oxford vaccine, granted its first approval by Britain last week, is cheaper and easier to use than some rival shots, such as one from Pfizer, Inc. — a major advantage in tackling a pandemic that has claimed more than 1.8 million lives worldwide.

The British shot, however, has been plagued by uncertainty about its most effective dosage ever since data published in November showed a half dose followed by a full dose had a 90% success rate, while two full shots were 62% effective.

The efficacy of the Indian vaccine could “go up much more” than 60% after two doses are given, a source with knowledge of the matter told Reuters. Bharat Biotech earlier said they could produce up to 300 million doses a year.

“While this vaccine addresses an unmet medical need during this pandemic, our goal is to provide global access to populations that need it the most,” the company’s chairman, Krishna Ella, said. “COVAXIN has generated excellent safety data with robust immune responses.”

An opposition lawmaker and former minister, however, questioned the approval process for COVAXIN.

“Bharat Biotech is a first-rate enterprise, but it is puzzling that internationally accepted protocols relating to phase 3 trials are being modified for Covaxin,” Jairam Ramesh wrote on Twitter.

India’s regulator has also received an emergency-use application for the COVID-19 vaccine made by Pfizer and Germany’s BioNTech — the first shot to secure regulatory approval in the West.

India has reported more than 10.3 million COVID-19 cases and around 150,000 deaths, though its infection rate has come down significantly from a mid-September peak.

SII plans to sell the AstraZeneca/Oxford vaccine to the Indian government at about 250 rupees ($3.42) per dose and 1,000 rupees on the private market.

The regulator on Sunday also gave permission to Cadila Healthcare Ltd. to conduct Phase-III clinical trials on 26,000 Indian participants for its DNA-platform vaccine candidate, saying the interim trial data had shown it was “safe” and prompted an immune response under a three-dose regimen. — Reuters

Britain will allow mixing of vaccines on rare occasions

A test tube labeled with the vaccine is seen in front of AstraZeneca logo in this illustration taken, Sept. 9, 2020. — REUTERS/DADO RUVIC

LONDON — Britain will allow people to be given shots of different coronavirus disease 2019 (COVID-19) vaccines on rare occasions, despite a lack of evidence about the extent of immunity offered by mixing doses.

In a departure from other strategies globally, the government said people could be given a mix-and-match of two COVID-19 shots, for example if the same vaccine dose was out of stock, according to guidelines published on New Year’s Eve.

“(If) the same vaccine is not available, or if the first product received is unknown, it is reasonable to offer one dose of the locally available product to complete the schedule,” according to the guidelines.

Mary Ramsay, head of immunizations at Public Health England (PHE), said this would only happen on extremely rare occasions, and that the government was not recommending the mixing of vaccines, which require at least two doses given several weeks apart.

“Every effort should be made to give them the same vaccine, but where this is not possible it is better to give a second dose of another vaccine than not at all,” she said.

COVID-19 has killed more 74,000 people in Britain — the second-highest death toll in Europe, and health officials are racing to deliver doses to help end the pandemic as fears grow that the health service could be overwhelmed.

Earlier this week, the government reactivated emergency hospitals built at the start of the outbreak as wards fill up with COVID-19 patients.

Britain has been at the forefront of approving the new coronavirus vaccines, becoming the first country to give emergency authorization to the Pfizer/BioNTech and the AstraZeneca/University of Oxford vaccines last month.

Both vaccines are meant to be administered as two shots, given several weeks apart, but they were not designed to be mixed together.

The government’s new guidelines said there “is no evidence on the interchangeability of the COVID-19 vaccines although studies are underway.”

However, the advice said that while every effort should be made to complete the dosing regimen with the same vaccine, if the patient is at “immediate high risk” or is considered “unlikely to attend again” they can be given different vaccines. 

Britain sparked controversy earlier this week by announcing plans to delay giving the coronavirus vaccine booster shot in an attempt to ensure more people could be given the more limited protection conferred by a single dose.

The top US infectious diseases expert, Anthony Fauci, said on Friday he did not agree with the British approach of delaying the second dose up to 12 weeks.

“I would not be in favour of that,” he told CNN. “We’re going to keep doing what we’re doing.” — Reuters

Russia inoculates over 800,000 people against coronavirus

MOSCOW — More than 800,000 people in Russia have been inoculated so far against the new coronavirus and more than 1.5 million vaccine doses have been dispatched, Health Minister Mikhail Murashko said on Saturday.

Russia, which began rolling out its Sputnik V vaccine in early December, has the world’s fourth higher number of coronavirus disease 2019 (COVID-19) cases and is putting high hopes on several vaccines it plans to produce.

From Jan. 1, people who are inoculated in Russia will get an electronic vaccination certificate, the TASS news agency quoted Mr. Murashko as saying. The ministry is keeping a database of Russians who have been vaccinated, TASS reported.

The Sputnik V vaccine, which Russia already started supplying to other countries, is administered in two doses, which use different components, 21 days apart.

Russia sent 300,000 doses of the vaccine to Argentina last week, causing frustration at home, with some people arguing that more shots should be made available at home.

On Saturday, Russia reported 26,301 new coronavirus cases in the last 24 hours, taking its total caseload to 3,212,637.

Authorities said 447 people had died in the past 24 hours, taking the official death toll to 58,002. — Reuters

PBA still assessing direction to take for Season 46 — Marcial

By Michael Angelo S. Murillo, Senior Reporter

RECOGNIZING that it still has to deal with the coronavirus pandemic in 2021, the Philippine Basketball Association (PBA) is not rushing and is carefully assessing the direction to take for its Season 46.

In an interview over the Power and Play with Noli Eala radio program on Saturday, PBA Commissioner Willie Marcial shared that the league is still in the process of weighing its options.

Nothing is definite yet as far as the kind of form its next season will take, considering how fluid the situation is with the pandemic, which remains a concern.

They, however, said they will try to start Season 46 on the league’s anniversary on April 9 either in another “bubble” setup or a closed-circuit setting.

“We’ll see what the situation is with the vaccine, if by April there will be one already. We’re looking at the type of bubble the season would be played, the venue, the economy, and whether the government would allow the PBA to play. I cannot answer that at the moment. But maybe by February or March, we’ll have more clarity,” said Mr. Marcial.

The PBA chief went on to say that the aim is still to have a full complement of three conferences this year, but if it is not possible, they are angling to at least have two.

Whether the league would have an import-laden tournament is still up in the air, Mr. Marcial said, as it hinges on the prevailing conditions with the pandemic by that time.

The PBA is coming off a successful bubble tournament at Clark City in Angeles City, Pampanga, from October to early December after activities were suspended because of the pandemic early last year.

In the bubble, participants were holed up in a controlled environment in Clark for the duration of the tournament, following strict health and safety protocols to guard against the spread of the coronavirus.

It hit some rough patches, including “positive scare,” but the league was able to survive it and finish the Philippine Cup with the Barangay Ginebra San Miguel Kings crowned as champions.

Mr. Marcial said the bubble did not come cheap, amounting to some P70 million to be staged, but he was happy to report that they were somehow able to recover it although he did not provide details.

Given that, they are factoring it as well in planning for Season 46.

An alternative setup is the closed-circuit setting, which was employed during the team practices in the lead up to the tournament bubble.

In it, players have their travel limited as much as possible to home-to-game venue and back, and their movements and health monitored closely by their teams and the league to preserve the integrity of the tournament.

Mr. Marcial shared that provisions for vaccines are also being planned by the league.

“I hope we can buy the vaccine for the players and those who are in need. Maybe the teams can carry the costs for that. They can shoulder the vaccination for their own players, and we’ll vaccinate our own employees and referees,” he said.

He was quick to say though they have not talked to the government about it yet but they are already laying down the plan just in case.

THE DRAFT
Meanwhile, Mr. Marcial said the deadline for application for this year’s rookie draft is on Jan. 27 with the draft itself happening on March 14.

Details for the draft are still being finalized, including if there will be another special Gilas draft just like last time around.

“We’ll meet with the board of governors after all the applications are in to decide on how the drafting will go. The SBP (Samahang Basketbol ng Pilipinas) hasn’t decided yet whether or not they need one (Gilas draft) because they don’t know who will declare for the draft,” said Mr. Marcial.

In the last rookie draft, a special selection was made for Gilas in line with the SBP mission of putting a pool of players who will be available for the national team for future competitions, including the 2023 FIBA World Cup, where the Philippines is one of the hosts.

Selected in the draft were Isaac Go, Rey Suerte, Matt and Mike Nieto, and Allyn Bulanadi.

Mr. Marcial said that because of the pandemic, there will be no draft combine this year, but he is bullish of the kind of talent available.

“For sure, we’ll reach the third and fourth round. There are a lot of players available, including those who graduated from the UAAP (University Athletic Association of the Philippines) and the NCAA (National Collegiate Athletic Association), and those from the MPBL (Maharlika Pilipinas Basketball League) and those from Chooks-to-Go Pilipinas 3×3 who said they will enter.”

NY Knicks squeak out a win over Indiana Pacers, 106-102

AUSTIN Rivers hit a 3-pointer that gave the New York Knicks the lead for good late in the fourth quarter Saturday night and added the clinching layup with 35.3 seconds remaining as the Knicks surprised the host Indiana Pacers, 106-102.

Rivers, who played his second game for the Knicks after missing the first four games due to a groin injury, scored 15 points off the bench for New York, which has won three of four.

RJ Barrett scored a team-high 25 points and was four of five on 3-point attempts. The Knicks hit 44.4% (12 of 27) of their 3-pointers Saturday, two nights after shooting a franchise record-low of 8.3% (three of 36) from the 3-point line. Julius Randle finished with 12 points and 11 rebounds, Elfrid Payton had 19 points and eight rebounds, and Mitchell Robinson went of 8 of 10 shooting and netted 16 points.

Malcolm Brogdon scored 33 points for the Pacers, who have lost two of three. Domantas Sabonis (13 points, 13 rebounds) had his sixth double-double in as many games to start the season, while Myles Turner scored 17 points. Victor Oladipo finished with 16 points, and Justin Holiday added 12 points off the bench.

ROCKETS 102 – KINGS 94
John Wall had game highs of 28 points, six assists and three steals as host Houston capped a back-to-back sweep of Sacramento.

Rockets guard James Harden, who poured in 33 points with eight assists in a 122-119 victory over the Kings on New Year’s Eve, was a late scratch with a right ankle sprain. Houston found sufficient scoring elsewhere, with Eric Gordon replacing Harden and recording 21 points. Christian Wood notched his third double-double for the Rockets with 20 points and 15 rebounds. — Reuters

PSC seeking to build on gains and finish strong

WHILE admitting that its run under the current administration is anything but perfect, the Philippine Sports Commission (PSC) is nonetheless happy over what it has achieved and looking to build on the gains it has had and finish strong.

Anchored on a five-year development plan, the PSC said that, by and large, it succeeded in seeing its mission and vision through under the government of President Rodrigo R. Duterte.

“I think we have built legacies that we are happy to leave and for others to follow through on,” said PSC Chairman William Ramirez as he gave the agency’s yearend report in December.

“It’s not 100%, but I believe we have been able to put up strong points,” he added.

Mr. Ramirez shared that since they took office, they have made the PSC a better organization, enhancing its capability and accountability to lead, manage, implement, and assess sports programs in the country.

It also was able to highlight the important role that sports play in personal and community development and the need to shore up the country’s grassroots development push by making sports more accessible with the end view of producing globally competitive athletes.

The institutionalization of Philippine Sports Institute, the country’s training, educational and research center, is another development that they are proud of, Mr. Ramirez said, as it complemented the PSC’s programs geared towards the development of grassroots sports, high-performance sports, and professional development of sports practitioners.

Since 2016, the PSC has also managed to fix sports facilities worn out by time under its watch, including the Rizal Memorial Sports Complex and Philsports Multipurpose Complex, while at the same erecting some new ones.

And there are the linkages it has formed with various organizations and agencies, which Mr. Ramirez said has gone a long way in the agency successfully fostering good relationships to make things happen.

“I think our biggest achievement is the creation of a sports development highway in the Philippines, where we have coordinators assigned to different places in the country and the PSC establishing partnerships with LGUs (local government units) and DepED (Department of Education). These partnerships are very important in seeing our various programs succeed,” the PSC chief said.

Mr. Ramirez also lauded the national athletes’ performance in international competitions of late, including the 2018 Asian Games and the 2019 Southeast Asian Games (SEA), where they did well and improved on their previous showing.

It is something the PSC hopes will continue this year in the Tokyo Olympics and SEA Games in Vietnam.

For the remaining one and a half years, Mr. Ramirez said it is about staying the course amid the challenges presented by the coronavirus pandemic.

“In our remaining time, we will continue to navigate and review what we have put up, so we can provide a good plan for the next PSC officials to follow. The issue with the pandemic makes it tougher, but with partnerships with DepEd, the Philippine Olympic Committee, the national sports associations, and others, I think we will be able to accomplish that,” he said. — Michael Angelo S. Murillo

Real Madrid see off Celta Vigo, 2-0, to return to La Liga summit

MADRID — Real Madrid beat an in-form Celta Vigo 2-0 at home on Saturday thanks to a goal and assist apiece from Spanish pair Lucas Vázquez and Marco Asensio, putting the side above city rivals Atlético Madrid at the top of La Liga.

The win took the Spanish champions to the summit on 36 points, one ahead of second-placed Atletico who has three games in hand and on Sunday visits Alavés.

Real was smarting from a surprise 1-1 draw at struggling Elche in their last match and were missing captain Sergio Ramos, who was out with a stomach bug.

But they got off to an ideal start thanks to a towering header from Vázquez, who out-jumped two Celta defenders to power home a cross from Asensio.

Vázquez returned the favor early in the second half to tee up Asensio after Madrid had recovered the ball high in Celta’s half. Zinedine Zidane’s side comfortably saw out the victory, ending Celta’s unbeaten run of six games under new coach Eduardo Coudet.

Celta had won five of their previous six league games since Argentine Coudet took charge in November after Óscar Garcia was sacked, taking them from the bottom of the standings to within striking distance of the European places.

The trip to Madrid was their biggest test so far and they almost took the lead when talismanic striker Iago Aspas ran through and knocked the ball past keeper Thibaut Courtois, but Real defender Nacho recovered to clear it off the line.

Madrid broke immediately with a long ball to Asensio, whose cross was nodded in by Vázquez.

Real nearly doubled their lead when Dani Carvajal tried his luck from outside the box and saw his shot whistle past the post. — Reuters

Uncertainty

The end of 2020 saw Major League Baseball licking its wounds and pondering how it should navigate a new year filled with just as much uncertainty. Considering the potential for continued losses, franchises are determined to cut back on expenses. And, naturally, payroll becomes the first casualty; for the first time in a long while, the offseason, traditionally host to a flurry of activity in which talent is sought by all and sundry, figures to be one of reflection and not action. Except, that is, for the Padres, who see a break while others recoil with caution.

Make no mistake. The Padres are taking a significant risk. Such is the nature of competition in the sport that roster improvements, no matter how seemingly substantial, often translate to marginal returns. The best players increase win probabilities, but do not bring with them certainty of ultimate success. And, in the midst of a pandemic that has all but wiped out the usual revenue sources, investing in marquee names comes at high cost but guarantees little. Nonetheless, the small-market outfit dared to dream big and pull the trigger on a couple of deals slated to further lift its profile.

Indeed, the addition of Blake Snell and Yu Darvish provides the Padres with a fearsome rotation frontline designed to turn it from a middling competitor into a bona fide contender. No doubt, they wouldn’t have thumbed up the trades had they been compelled to hand over more than a single regular and farm system prospects in return. And, no doubt, they wouldn’t have so much as thought of doing, so were they not already close to challenging the powerhouse Dodgers in the National League West.

The Padres were likewise fortunate, to be sure. They pounced on the Cubs’ apparent need to let Darvish go in order to trim outlays, as well the Rays’ evident urge to flip Snell early in the face of a hazy outlook. Then again, the boldest make their own fortunes. And should their gamble pay off, the rest of the league will be left to second-guess a pronounced failure to discern opportunity in crisis. In any case, there is benefit to establishing a culture that moves for continuous improvement and rewards resourcefulness.

Baseball etches nothing in stone. At the same time, there can be no discounting the value good vibes bring to effort. Ask Snell, Darvish, and free-agent acquisition Ha-seong Kim, who feel wanted by the Padres. Ask Manny Machado and Fernando Tatis Jr., who welcome the arrival of fellow top-shelf players. And ask the fans, who appreciate owner Peter Seidler’s against-the-current disposition. The hardware may not be a sure thing, but, in the eyes of the aforementioned, they’re already champions.

 

Anthony L. Cuaycong has been writing Courtside since BusinessWorld introduced a Sports section in 1994. He is a consultant on strategic planning, operations and Human Resources management, corporate communications, and business development.